Bayer Acquires German Biotech Start-up Targenomix

Targenomix, a spin-off of the Max Planck Institute for Molecular Plant Physiology, will contribute to Bayer’s Crop Science R&D pipeline by continuing to deliver novel systems biology approaches for innovative crop protection discovery / Targenomix…

4 Min
More

First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial

Berlin/Aalborg, 27 October 2022. The University Hospital Aalborg (Denmark) yesterday has imaged the first patient with Eckert and Ziegler’s Gallium (68Ga) boclatixafortide (PENTIXAFOR) in an international phase 2 trial.

3 Min
More

T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial

The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with MAGE-A1 positive solid tumors

 

TK-8001 targets a MAGE-A1 epitope presented on HLA-A*02:01

 

IMAG1NE…

5 Min
More

FyoniBio and Strike Pharma sign a Master Service Agreement covering Cell Line Development for a novel bi-specific therapeutic mAb

Berlin, Germany and Stockholm, Sweden, October 20, 2022:

FyoniBio, a CDO expert specialized in tailored cell line development and Strike Pharma, whose proprietary

Adaptable Drug Affinity Conjugate (ADAC) technology enables development of …

2 Min
More

Special Topic | Long COVID in Berlin-Brandenburg – research, networks and engagement for better care

The term “Long COVID” first emerged in the social media. Numerous affected individuals have reported in the social media about their various, long-lasting health limitations after SARS-CoV-2 infection. In the Berlin-Brandenburg metropolitan region,…

6 Min
More

Berlin-based clinical trials imaging company pharmtrace opens US base

pharmtrace, a German, Berlin based provider of Independent expertise for nuclear medicine, diagnostics, and drug development clinical trials has established a representative office in Philadelphia. pharmtrace is currently enjoying increasing…

1 Min
More

NUVISAN receives US$ 9.6m grant for a multi-target drug discovery program on novel non-hormonal contraceptive medicines

NUVISAN’s integrated drug discovery expertise leveraged in a grant from the Bill & Melinda Gates Foundation

2 Min
More

Scientists from Charité profiled 168 metabolic markers in blood samples and were able to predict the risk of onset of several diseases with just one test

To prevent diseases from occurring in the first place, it is important to identify those individuals who are at particularly high risk as early as possible. Yet current screening methods are often costly and focus only on one disease at a time.…

4 Min
More

Keeping aggressive cancer cells in check

BRCA1/2-mutated tumor cells often survive treatment, whether it’s chemo- or radiotherapy, because they can repair therapy-induced DNA damage. A team led by Claus Scheidereit of the Max Delbrück Center has now reported in The EMBO Journal how blocking…

4 Min
More

MDC team has explained the pivotal role of the transcription factor C/EBPb in the secretion process in the lungs’ alveoli

If a secretion in the lungs’ alveoli is not cleared regularly, breathing difficulties can develop. In a study published in Science Immunology, a team led by Alexander Mildner and Achim Leutz has now explained the pivotal role of the transcription…

4 Min
More
Show more items